[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eton Pharmaceutcials Inc (ETON)

Eton Pharmaceutcials Inc (ETON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,757,283
  • Shares Outstanding, K 28,583
  • Annual Sales, $ 79,950 K
  • Annual Income, $ -4,600 K
  • EBIT $ 16 M
  • EBITDA $ 21 M
  • 60-Month Beta 0.86
  • Price/Sales 22.68
  • Price/Cash Flow 12,237.61
  • Price/Book 37.30

Options Overview Details

View History
  • Implied Volatility 66.28% (-0.52%)
  • Historical Volatility 120.84%
  • IV Percentile 4%
  • IV Rank 8.04%
  • IV High 188.51% on 03/05/26
  • IV Low 55.60% on 09/02/25
  • Expected Move (DTE 29) 7.23 (12.06%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 837
  • Volume Avg (30-Day) 434
  • Put/Call OI Ratio 0.62
  • Today's Open Interest 8,111
  • Open Int (30-Day) 5,773
  • Expected Range 52.69 to 67.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $0.16
  • Number of Estimates 2
  • High Estimate $0.17
  • Low Estimate $0.15
  • Prior Year $-0.07
  • Growth Rate Est. (year over year) +328.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.61 +47.53%
on 08/11/26
63.83 -6.14%
on 08/19/26
+18.84 (+45.87%)
since 07/20/26
3-Month
26.66 +124.72%
on 06/03/26
63.83 -6.14%
on 08/19/26
+25.46 (+73.90%)
since 05/20/26
52-Week
14.27 +319.83%
on 02/05/26
63.83 -6.14%
on 08/19/26
+43.36 (+261.99%)
since 08/20/25

Most Recent Stories

More News
Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results

Record revenue, with Q2 2026 product sales of $37.6 million, representing 99% growth over Q2 2025 Q2 2026 fully diluted GAAP EPS of $0.35, non-GAAP fully diluted EPS of $0.43; EBITDA of $14.1 million,...

ETON : 59.91 (-2.55%)
Eton Pharmaceuticals: Can Eleven Rare Disease Products Actually Translate Into Profitability?

Barchart Research What to Expect from ETON Earnings ETON Generated August 12, 2026 Current Price $41.58 EPS Estimate $$0.11 Consensus Rating Moderate Buy Average Move 6.56% Eton Pharmaceuticals: Can Eleven...

ETON : 59.91 (-2.55%)
Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001

ASN-001 targets the substantially larger population of moderate infantile hemangiomas currently treated off-label with topical timolol Complementary product to HEMANGEOL ® (propranolol hydrochloride)...

ETON : 59.91 (-2.55%)
Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

DEER PARK, Ill., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...

ETON : 59.91 (-2.55%)
Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution

FDA submission seeks to bring KHINDIVI to larger pediatric patient population within the adrenal insufficiency market New formulation successfully demonstrated bioequivalence to ALKINDI SPRINKLE ® ...

ETON : 59.91 (-2.55%)
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)

IMPAVIDO ® is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania species Leishmaniasis is a rare but potentially life-threatening...

ETON : 59.91 (-2.55%)
Eton Pharmaceuticals Q1 Earnings Call Highlights

Eton Pharmaceuticals (NASDAQ:ETON) raised its 2026 revenue outlook after reporting record first-quarter product sales and highlighting early progress from two recent product launches, DESMODA and HEMANGEOL.Chief...

ETON : 59.91 (-2.55%)
Eton Pharmaceuticals Reports First Quarter 2026 Financial Results

Q1 2026 product sales of $24.3 million, representing 73% growth over Q1 2025 Raising full year revenue guidance - now expect 2026 revenue to exceed $120 million, up from previous guidance of $110 million...

ETON : 59.91 (-2.55%)
Eton Pharmaceuticals Reports Tomorrow After Missing Last Quarter's Consensus by Seven Cents

Barchart Research What to Expect from ETON Earnings ETON Generated May 13, 2026 Current Price $30.82 EPS Estimate $$0.10 Consensus Rating Strong Buy Average Move 6.46% Eton Pharmaceuticals Reports Tomorrow...

ETON : 59.91 (-2.55%)
Eton Pharmaceuticals to Participate in Upcoming Investor Conferences

DEER PARK, Ill., May 12, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...

ETON : 59.91 (-2.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Eton Pharmaceuticals Inc. operates as a development stage biotechnology company. Its product pipeline consists of DS-300, EM-100, DS-100, DS-200, ET-103, ET-101, ET-102 and CT-100 which are in clinical stage. Eton Pharmaceuticals Inc. is based in Deer Park, Illinois.

See More

Key Turning Points

3rd Resistance Point 64.79
2nd Resistance Point 63.68
1st Resistance Point 61.80
Last Price 59.91
1st Support Level 58.81
2nd Support Level 57.70
3rd Support Level 55.82

See More

52-Week High 63.83
Last Price 59.91
Fibonacci 61.8% 44.90
Fibonacci 50% 39.05
Fibonacci 38.2% 33.20
52-Week Low 14.27

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.